Linked Life Data

10360607

Source:http://linkedlifedata.com/resource/pubmed/id/10360607

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10360607rdf:typepubmed:Citationlld:pubmed
pubmed-article:10360607lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10360607lifeskim:mentionsumls-concept:C0007131lld:lifeskim
pubmed-article:10360607lifeskim:mentionsumls-concept:C0011777lld:lifeskim
pubmed-article:10360607lifeskim:mentionsumls-concept:C0246415lld:lifeskim
pubmed-article:10360607lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:10360607lifeskim:mentionsumls-concept:C0033045lld:lifeskim
pubmed-article:10360607lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:10360607lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:10360607pubmed:issue3lld:pubmed
pubmed-article:10360607pubmed:dateCreated1999-7-15lld:pubmed
pubmed-article:10360607pubmed:abstractTextWe performed a Phase II trial to evaluate the activity and tolerability of docetaxel as a single agent in the treatment of advanced non-small cell lung cancer (NSCLC). Forty-four patients with metastatic and/or locally advanced NSCLC received i.v. docetaxel 100 mg/m2 every 3 weeks for a median of 4 (range 1-11) cycles. All patients received premedication with oral dexamethasone 8 mg twice daily for 5 days starting the day before chemotherapy. Seven partial responses were observed among 35 evaluable patients, and the overall response rate was 20% (95% CI 8-37). The median response duration was 5 months, median survival time was 10 months and the estimated 1-year survival rate was 42%. Treatment was generally well tolerated. Febrile neutropenia occurred in 10 patients (23%); neutropenic infection occurred in 4 patients, and led to 2 toxic deaths (both patients had borderline exclusion criteria). The corticosteroid premedication effectively reduced the overall incidence (34%) and severity (4% severe) of fluid retention, and delayed the median time to onset from cycle 4 to cycle 7. This study shows the promising efficacy of docetaxel as monotherapy in advanced NSCLC, and combination chemotherapy regimens incorporating docetaxel are now being evaluated in this clinical setting.lld:pubmed
pubmed-article:10360607pubmed:languageenglld:pubmed
pubmed-article:10360607pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10360607pubmed:citationSubsetIMlld:pubmed
pubmed-article:10360607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10360607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10360607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10360607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10360607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10360607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10360607pubmed:statusMEDLINElld:pubmed
pubmed-article:10360607pubmed:issn0167-6997lld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:DelormeFFlld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:ShepherdF AFAlld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:LatreilleJJlld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:MaksymiukA...lld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:LabergeFFlld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:HirseSSlld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:GelmonK AKAlld:pubmed
pubmed-article:10360607pubmed:authorpubmed-author:BérilleJJlld:pubmed
pubmed-article:10360607pubmed:issnTypePrintlld:pubmed
pubmed-article:10360607pubmed:volume16lld:pubmed
pubmed-article:10360607pubmed:ownerNLMlld:pubmed
pubmed-article:10360607pubmed:authorsCompleteYlld:pubmed
pubmed-article:10360607pubmed:pagination265-70lld:pubmed
pubmed-article:10360607pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:meshHeadingpubmed-meshheading:10360607...lld:pubmed
pubmed-article:10360607pubmed:articleTitlePhase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience.lld:pubmed
pubmed-article:10360607pubmed:affiliationCentre Hospitalier de l'Université de Montréal, Quebec, Canada. jlatrei@cam.orglld:pubmed
pubmed-article:10360607pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10360607pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10360607pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:10360607pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:10360607pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed